Abstract
We report the discovery of chroman 28, a potent and selective antagonist of human, nonhuman primate, rat, and rabbit bradykinin B1 receptors (0.4-17 nM). At 90 mg/kg s.c., 28 decreased plasma extravasation in two rodent models of inflammation. A novel method to calculate entropy is introduced and ascribed ∼30% of the gained affinity between "flexible" 4 (Ki = 132 nM) and "rigid" 28 (Ki = 0.77 nM) to decreased conformational entropy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 607-610 |
| Number of pages | 4 |
| Journal | Journal of Medicinal Chemistry |
| Volume | 50 |
| Issue number | 4 |
| DOIs | |
| State | Published - Feb 22 2007 |
| Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Drug Discovery
- Molecular Medicine
Fingerprint
Dive into the research topics of 'Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver